Search research articles
Contact Us
Filters
Showing results (31-40 of 75) with videos related to
Page
of 8
Sort By:
Bone Marrow Transplantation
|
December 2, 2022
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, et al.
European Journal of Haematology
|
May 2, 2018
Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning
Marie Robin, Kavita Raj, Sylvie Chevret, et al.
Blood Advances
|
October 25, 2019
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
Vipul Sharad Sheth, Victoria Potter, Shreyans A Gandhi, et al.
Bone Marrow Transplantation
|
September 28, 2019
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)
Jesus Feliu, Victoria Potter, Francesco Grimaldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
Ali Bazarbachi, Christoph Schmid, Myriam Labopin, et al.
Blood Advances
|
April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
Justin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 5, 2025
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK
Paolo Antonio Muraro, Majid Kazmi, Eleonora De Matteis, et al.
Bone Marrow Transplantation
|
March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
Gesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Bone Marrow Transplantation
|
June 29, 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Enrico Maffini, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Frontiers in Oncology
|
July 30, 2019
Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different <i>in vivo</i> Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience
Vipul Sheth, Vanessa Kennedy, Hugues de Lavallade, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 75) with videos related to
Sort By:
Page
of 8
Bone Marrow Transplantation
|
December 2, 2022
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, et al.
European Journal of Haematology
|
May 2, 2018
Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning
Marie Robin, Kavita Raj, Sylvie Chevret, et al.
Blood Advances
|
October 25, 2019
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
Vipul Sharad Sheth, Victoria Potter, Shreyans A Gandhi, et al.
Bone Marrow Transplantation
|
September 28, 2019
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)
Jesus Feliu, Victoria Potter, Francesco Grimaldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
Ali Bazarbachi, Christoph Schmid, Myriam Labopin, et al.
Blood Advances
|
April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
Justin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 5, 2025
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK
Paolo Antonio Muraro, Majid Kazmi, Eleonora De Matteis, et al.
Bone Marrow Transplantation
|
March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
Gesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Bone Marrow Transplantation
|
June 29, 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Enrico Maffini, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Frontiers in Oncology
|
July 30, 2019
Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different <i>in vivo</i> Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience
Vipul Sheth, Vanessa Kennedy, Hugues de Lavallade, et al.
Page
of 8